Reports
Sale
Europe Multiplexed Diagnostics Market Size, Share, Growth: By Product Type: Reagents & Consumables, Instruments and Accessories, Others; By Application: Infectious Disease, Oncology, Autoimmune Diseases, Cardiac Diseases, Allergies, Others; By Technology; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Europe Multiplexed Diagnostics Market Outlook
The global multiplexed diagnostics market size was valued at USD 12.9 billion in 2023, with Europe holding a significant market share. The market is driven by the rising advancements in diagnostic technology. It is expected to grow at a CAGR of 15.2% during the forecast period of 2024-2032, with the values likely to attain USD 14.9 billion by 2032.
Key Takeaways
- Recent data suggests that 1 out of 3 adults in the European Union (EU) are estimated to have a chronic disease. The rising prevalence of chronic diseases is expected to directly impact market demand.
- One of the significant Europe multiplexed diagnostics market trends is the increased investment in multiplexed technologies to develop novel diagnostic solutions. In May 2023, Delta Diagnostics secured EUR 5.25 million in funding to support the development and marketing of its low-cost, rapid, and sensitive biosensor system for real-time biomolecule detection.
- The favorable regulatory environment is ensuring accelerated approvals and reduced time-to-market in the region. In October 2023, a leading diagnostic company AliveDx received three IVDR CE marks for its automated MosaiQ solution, designed for rapid diagnosis of connective tissue diseases (CTD).
Europe Multiplexed Diagnostics Market Analysis
Multiplexing allows simultaneous detection and identification of multiple biomarkers in a single test. Multiplexed platforms help in the accurate diagnosis of various diseases along with offering insights into selecting the most effective treatment for a specific patient. The increased adoption of multiplexed diagnostic methods can be attributed to the advantages associated with these techniques such as reduced time and cost per analysis. Moreover, the growing interest in personalized medicine and the continuous technological advancements are expected to drive the Europe multiplexed diagnostics market growth in the forecast period.
In Europe, the prevalence of chronic diseases and infectious diseases is rapidly increasing. This impacts the market demand significantly. Recent data suggests that 1 out of 3 adults in the European Union (EU) are estimated to have a chronic disease. Moreover, the rising geriatric population in the region also fuels the demand for effective and affordable diagnostic techniques, as multi-morbidity (having two or more chronic conditions) rates are reported to be high in this population base. Thus, the rising prevalence of chronic diseases coupled with the growing elderly patient base is projected to boost Europe multiplexed diagnostics market share in the coming years.
The market whichs witnessing a favorable regulatory environmentwhichch ensures accelerated approvals and reduced time-to-market in the region. In October 2023, a leading diagnostic company AliveDx received three IVDR (In-Vitro Diagnostics Regulation) CE marks for its automated MosaiQ solution, designed for rapid diagnosis of connective tissue diseases (CTD). The in-vitro diagnostics solution included MosaiQ Centromere Protein B (CENP-B) microarray, MosaiQ AiPlex CTD multiplexed microarray immunoassays, and MosaiQ AiPlex CTD Quality. These high throughput platforms can enable rapid turnaround times even for complex diagnostic pathways. The increased availability of CE-marked multiplexed testing portfolios in the European Union and other regions is likely to fuel Europe multiplexed diagnostics market demand.
One of the notable trends is the increased investment in multiplexed technologies to develop novel diagnostic solutions. In May 2023, Delta Diagnostics (a biotechnology company) secured EUR 5.25 million in funding led by a consortium of 4 investors to support the development and marketing of its low-cost, rapid, and sensitive biosensor technology. The company’s biosensor method enables multiplexing for simultaneous analysis of biomolecules and can expedite life science research. Such substantial funding supports product development and its subsequent commercialization, is anticipated to propel market growth in the coming years.
Europe Multiplexed Diagnostics Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Product Type | Reagents, Consumables, Instruments and Accessories, Others |
| Application | Infectious Disease, Oncology, Autoimmune Diseases, Cardiac Diseases, Allergies, Disease Diagnostics, Molecular Diagnostics, Others |
| Technology | Low Density Multiplexed Assays, Medium Density Multiplexed Assays, High Density Multiplexed Assays, Very High Density Multiplexed Assays, Next-Generation Sequencing Assays, Others |
| End User | Hospitals, Pharmaceutical Companies, Clinical Research Organizations, Academic Research Institutes, Diagnostic Laboratories, Others |
| Countries | United Kingdom, Germany, France, Italy, Others |
Europe Multiplexed Diagnostics Market: Competitor Landscape
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Agilent Technologies Inc
- F. Hoffmann-La Roche Ltd
- BioMerieux
- Illumina, Inc
- Hologic, Inc
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories Inc.
- Siemens Healthineers AG
- Boston Scientific Corporation
- Diasorin S.p.A
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Application |
|
| Breakup by Technology |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Europe Multiplexed Diagnostics Market Overview
3.1 Europe Multiplexed Diagnostics Market Historical Value (2017-2023)
3.2 Europe Multiplexed Diagnostics Market Forecast Value (2024-2032)
4 Europe Multiplexed Diagnostics Market Landscape*
4.1 Europe Multiplexed Diagnostics Market : Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Europe Multiplexed Diagnostics Market : Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Application
4.2.3 Analysis by Technology
5 Europe Multiplexed Diagnostics Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Europe Multiplexed Diagnostics Market Segmentation (2017-2032)
6.1 Europe Multiplexed Diagnostics Market (2017-2032) by Product Type
6.1.1 Market Overview
6.1.2 Reagents & Consumables
6.1.3 Instruments and Accessories
6.1.4 Others
6.2 Europe Multiplexed Diagnostics Market (2017-2032) by Application
6.2.1 Market Overview
6.2.2 Infectious Disease
6.2.3 Oncology
6.2.4 Autoimmune Diseases
6.2.5 Cardiac Diseases
6.2.6 Allergies
6.2.7 Disease Diagnostics
6.2.8 Molecular Diagnostics
6.2.9 Others
6.3 Europe Multiplexed Diagnostics Market (2017-2032) by Technology
6.3.1 Market Overview
6.3.2 Low Density Multiplexed Assays
6.3.3 Medium Density Multiplexed Assays
6.3.4 High Density Multiplexed Assays
6.3.5 Very High Density Multiplexed Assays
6.3.6 Next-Generation Sequencing Assays
6.3.7 Others
6.4 Europe Multiplexed Diagnostics Market (2017-2032) by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Pharmaceutical Companies
6.4.4 Clinical Research Organizations
6.4.5 Academic Research Institutes
6.4.6 Diagnostic Laboratories
6.4.7 Others
6.5 Europe Multiplexed Diagnostics Market (2017-2032) by Countries
6.5.1 Market Overview
6.5.2 United Kingdom
6.5.3 Germany
6.5.4 France
6.5.5 Italy
6.5.6 Others
7 United Kingdom Multiplexed Diagnostics Market (2017-2032)
7.1 United Kingdom Multiplexed Diagnostics Market (2017-2032) by Product Type
7.1.1 Market Overview
7.1.2 Reagents & Consumables
7.1.3 Instruments and Accessories
7.1.4 Others
7.2 United Kingdom Multiplexed Diagnostics Market (2017-2032) by Application
7.2.1 Market Overview
7.2.2 Infectious Disease
7.2.3 Oncology
7.2.4 Autoimmune Diseases
7.2.5 Cardiac Diseases
7.2.6 Allergies
7.2.7 Disease Diagnostics
7.2.8 Molecular Diagnostics
7.2.9 Others
7.3 United Kingdom Multiplexed Diagnostics Market (2017-2032) by Technology
7.3.1 Market Overview
7.3.2 Low Density Multiplexed Assays
7.3.3 Medium Density Multiplexed Assays
7.3.4 High Density Multiplexed Assays
7.3.5 Very High Density Multiplexed Assays
7.3.6 Next-Generation Sequencing Assays
7.3.7 Others
7.4 United Kingdom Multiplexed Diagnostics Market (2017-2032) by End User
7.4.1 Market Overview
7.4.2 Academic Research Institutes
7.4.3 Hospitals
7.4.4 Pharmaceutical Companies
7.4.5 Clinical Research Organizations
7.4.6 Diagnostic Laboratories
7.4.7 Others
8 Germany Multiplexed Diagnostics Market (2017-2032)
8.1 Germany Multiplexed Diagnostics Market (2017-2032) by Product Type
8.1.1 Market Overview
8.1.2 Reagents & Consumables
8.1.3 Instruments and Accessories
8.1.4 Others
8.2 Germany Multiplexed Diagnostics Market (2017-2032) by Application
8.2.1 Market Overview
8.2.2 Infectious Disease
8.2.3 Oncology
8.2.4 Autoimmune Diseases
8.2.5 Cardiac Diseases
8.2.6 Allergies
8.2.7 Disease Diagnostics
8.2.8 Molecular Diagnostics
8.2.9 Others
8.3 Germany Multiplexed Diagnostics Market (2017-2032) by Technology
8.3.1 Market Overview
8.3.2 Low Density Multiplexed Assays
8.3.3 Medium Density Multiplexed Assays
8.3.4 High Density Multiplexed Assays
8.3.5 Very High Density Multiplexed Assays
8.3.6 Next-Generation Sequencing Assays
8.3.7 Others
8.4 Germany Multiplexed Diagnostics Market (2017-2032) by End User
8.4.1 Market Overview
8.4.2 Academic Research Institutes
8.4.3 Hospitals
8.4.4 Pharmaceutical Companies
8.4.5 Clinical Research Organizations
8.4.6 Diagnostic Laboratories
8.4.7 Others
9 France Multiplexed Diagnostics Market (2017-2032)
9.1 France Multiplexed Diagnostics Market (2017-2032) by Product Type
9.1.1 Market Overview
9.1.2 Reagents & Consumables
9.1.3 Instruments and Accessories
9.1.4 Others
9.2 France Multiplexed Diagnostics Market (2017-2032) by Application
9.2.1 Market Overview
9.2.2 Infectious Disease
9.2.3 Oncology
9.2.4 Autoimmune Diseases
9.2.5 Cardiac Diseases
9.2.6 Allergies
9.2.7 Disease Diagnostics
9.2.8 Molecular Diagnostics
9.2.9 Others
9.3 France Multiplexed Diagnostics Market (2017-2032) by Technology
9.3.1 Market Overview
9.3.2 Low Density Multiplexed Assays
9.3.3 Medium Density Multiplexed Assays
9.3.4 High Density Multiplexed Assays
9.3.5 Very High Density Multiplexed Assays
9.3.6 Next-Generation Sequencing Assays
9.3.7 Others
9.4 France Multiplexed Diagnostics Market (2017-2032) by End User
9.4.1 Market Overview
9.4.2 Academic Research Institutes
9.4.3 Hospitals
9.4.4 Pharmaceutical Companies
9.4.5 Clinical Research Organizations
9.4.6 Diagnostic Laboratories
9.4.7 Others
10 Italy Multiplexed Diagnostics Market (2017-2032)
10.1 Italy Multiplexed Diagnostics Market (2017-2032) by Product Type
10.1.1 Market Overview
10.1.2 Reagents & Consumables
10.1.3 Instruments and Accessories
10.1.4 Others
10.2 Italy Multiplexed Diagnostics Market (2017-2032) by Application
10.2.1 Market Overview
10.2.2 Infectious Disease
10.2.3 Oncology
10.2.4 Autoimmune Diseases
10.2.5 Cardiac Diseases
10.2.6 Allergies
10.2.7 Disease Diagnostics
10.2.8 Molecular Diagnostics
10.2.9 Others
10.3 Italy Multiplexed Diagnostics Market (2017-2032) by Technology
10.3.1 Market Overview
10.3.2 Low Density Multiplexed Assays
10.3.3 Medium Density Multiplexed Assays
10.3.4 High Density Multiplexed Assays
10.3.5 Very High Density Multiplexed Assays
10.3.6 Next-Generation Sequencing Assays
10.3.7 Others
10.4 Italy Multiplexed Diagnostics Market (2017-2032) by End User
10.4.1 Market Overview
10.4.2 Academic Research Institutes
10.4.3 Hospitals
10.4.4 Pharmaceutical Companies
10.4.5 Clinical Research Organizations
10.4.6 Diagnostic Laboratories
10.4.7 Others
11 Regulatory Framework
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Funding and Investment Analysis
13.1 Analysis by Funding Instances
13.2 Analysis by Type of Funding
13.3 Analysis by Funding Amount
13.4 Analysis by Leading Players
13.5 Analysis by Leading Investors
13.6 Analysis by Geography
14 Partnership and Collaborations Analysis
14.1 Analysis by Partnership Instances
14.2 Analysis by Type of Partnership
14.3 Analysis by Leading Players
14.4 Analysis by Geography
15 Supplier Landscape
15.1 Market Share by Top 5 Companies
15.2 Agilent technologies inc
15.2.1 Financial Analysis
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 F. Hoffmann-La Roche Ltd
15.3.1 Financial Analysis
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 BioMerieux
15.4.1 Financial Analysis
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 IIIlumina,Inc
15.5.1 Financial Analysis
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Hologic,Inc
15.6.1 Financial Analysis
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Thermo Fisher Scientific Inc.
15.7.1 Financial Analysis
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Bio-Rad Laboratories Inc.
15.8.1 Financial Analysis
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Siemens Healthineers AG
15.9.1 Financial Analysis
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Boston Scientific Corporation
15.10.1 Financial Analysis
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Diasorin S.p.A
15.11.1 Financial Analysis
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
16 Europe Multiplexed Diagnostics Market – Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Key Opinion Leaders (KOL) Insights (Additional Insight)
18 Company Competitiveness Analysis (Additional Insight)
18.1 Very Small Companies
18.2 Small Companies
18.3 Mid-Sized Companies
18.4 Large Companies
18.5 Very Large Companies
19 Payment Methods (Additional Insight)
19.1 Government Funded
19.2 Private Insurance
19.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The Europe multiplexed diagnostics market size is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 15.2% during the forecast period of 2024-2032. It is likely to reach a market value of USD 46.2 billion by 2032.
The growing prevalence of chronic diseases as well as infectious diseases are fuelling the demand for the market.
One of the significant trends in the market is the increased investment in multiplexed technologies to develop novel diagnostic solutions. In May 2023, Delta Diagnostics secured EUR 5.25 million investment to support the development and marketing of its affordable, rapid, and precise biosensor system for real-time biomolecule detection.
Based on the product type, the market is segmented into reagents and consumables, instruments, and accessories, among others.
Technologies available in the market include low density multiplexed assays, medium density multiplexed assays, high density multiplexed assays, very high-density multiplexed assays, and next-generation sequencing assays, among others.
End users of multiplexed diagnostics are hospitals, pharmaceutical companies, clinical research organizations, academic research institutes, and diagnostic laboratories, among others.
Major applications of the market include infectious disease, oncology, autoimmune diseases, cardiac diseases, allergies, disease diagnostics, and molecular diagnostics, among others.
The market segmentation by countries includes the United Kingdom, Germany, France, and Italy, among others.
The key players in the market are Agilent Technologies Inc., F. Hoffmann-La Roche Ltd, BioMerieux, Illumina, Inc., Hologic, Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Siemens Healthineers AG, Boston Scientific Corporation, and Diasorin S.p.A.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER